Table 7.

Mean change from baseline QT_cF across dose groups and post-dosing time points in part 1

Time (h)	Mean	SE	90% CI		Mean	SE	90% CI
			Lower	Upper			Lower	Upper
	Placebo				Group A (5 mg)
0.5	−2.79	1.45	−5.35	−0.22	−2.50	0.92	−4.36	−0.64
1	−4.07	1.71	−7.10	−1.04	−2.17	1.38	−4.94	0.61
2	−2.64	1.12	−4.62	−0.66	0.17	1.40	−2.66	2.99
3	−2.57	1.46	−5.16	0.01	1.50	1.18	−0.87	3.87
4	−3.79	1.04	−5.63	−1.94	1.17	2.39	−3.64	5.98
6	−2.00	1.64	−4.91	0.91	2.50	3.59	−4.74	9.74
8	−2.71	1.62	−5.58	0.15	0.17	2.60	−5.07	5.41
12	−0.57	2.13	−4.35	3.21	0.00	3.02	−6.09	6.09
24	0.43	1.74	−2.65	3.51	0.00	2.45	−4.94	4.94

Time (h)	Group B (25 mg)				Group C (75 mg)
0.5	−4.83	2.15	−9.17	−0.50	−4.17	1.35	−6.89	−1.44
1	−2.67	2.30	−7.31	1.98	−3.50	1.48	−6.48	−0.52
2	−2.00	1.88	−5.79	1.79	−3.00	2.46	−7.96	1.96
3	−2.17	2.50	−7.20	2.86	−3.17	1.58	−6.35	0.02
4	1.50	2.11	−2.75	5.75	−1.00	2.45	−5.94	3.94
6	6.50	3.04	0.37	12.63	−4.50	2.31	−9.15	0.15
8	−1.67	2.69	−7.09	3.76	−3.00	1.65	−6.33	0.33
12	2.67	2.70	−2.78	8.12	−0.67	2.29	−5.28	3.95
24	3.83	6.23	−8.71	16.38	−0.33	1.52	−3.40	2.73

Time (h)	Group D (150 mg fasted)				Group D (150 mg fed)
0.5	−2.50	0.81	−4.12	−0.88	2.33	1.78	−1.26	5.93
1	−5.00	1.00	−7.02	−2.98	−3.00	2.05	−7.13	1.13
2	−3.67	1.50	−6.69	−0.65	−4.00	2.07	−8.16	0.16
3	−0.33	1.17	−2.70	2.03	−7.17	1.08	−9.34	−5.00
4	−1.33	1.12	−3.58	0.91	−6.17	1.68	−9.56	−2.78
6	−0.33	2.49	−5.34	4.68	0.00	2.58	−5.20	5.20
8	−1.50	3.13	−7.80	4.80	−2.50	2.91	−8.36	3.36
12	0.00	2.46	−4.96	4.96	0.83	2.40	−4.00	5.67
24	−1.00	1.90	−4.82	2.82	−3.83	2.24	−8.35	0.68

Time (h)	Group E (300 mg)				Group F (600 mg)
0.5	−2.00	0.86	−3.73	−0.27	−4.00	2.28	−8.60	0.60
1	−2.17	1.96	−6.11	1.78	−4.50	1.18	−6.87	−2.13
2	−2.67	0.56	−3.79	−1.54	−4.83	1.74	−8.34	−1.33
3	0.17	1.25	−2.35	2.68	−4.67	0.61	−5.91	−3.43
4	−2.17	0.40	−2.98	−1.36	−5.83	1.19	−8.24	−3.43
6	1.00	1.90	−2.82	4.82	−7.50	3.17	−13.89	−1.11
8	2.83	2.90	−3.02	8.68	−7.50	2.51	−12.56	−2.44
12	0.83	1.87	−2.93	4.60	−3.50	2.75	−9.05	2.05
24	−0.83	2.33	−5.53	3.86	−4.00	1.41	−6.85	−1.15